FDA's Abilify Smack-Down Boosts Imitator Drugs
The U.S. Food and Drug Administration's recent rejection of a challenge the manufacturer of popular antipsychotic Abilify Maintena brought against a highly similar rival product shows how drugmakers can tweak existing...To view the full article, register now.
Already a subscriber? Click here to view full article